EpiVax is a Rhode Island-based immunology company dedicated to applying its tools (in-silico, in-vitro, and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines.The company has various offerings, such as vaccine services, immunogenicity assessment, deimmunizaiton, laboratory services, and pipeline services.
The company has been developing a peptide-based, epitope-driven vaccine candidate for healthcare workers who are working during the COVID-19 pandemic. It has partnered with the GAIA Vaccine Foundation (GVF). The two entities are crowd-sourcing the funds and have pledged to make a free license available to developing countries who qualify for it.
The company's research is being conducted in conjunction with researchers at the University of Georgia's Center for Vaccines and Immunology.
Anne (Annie) S. De Groot, M.D.
Anthony G. Marcello
Clifford Grimm, MBA
EpiVax Accelerates COVID-19 Vaccine Development with UGA's Center for Vaccines and Immunology
March 4, 2020
EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countrie
Documentaries, videos and podcasts
Executive Suite 10/11/2015: EpiVax CEO Annie De Groot
October 8, 2015
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.